Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma

Protocol No
ECOG-EAF151
Principal Investigator
Jennifer Connelly
Phase
N/A
Summary
The purpose of this research study is to test whether the advanced perfusion MRI done prior to starting Bevacizumab and at two weeks after starting Bevacizumab can determine your response to the treatment better than the standard MRI performed at typical time points. The researchers want to see if this type of advanced MRI is better or the same as what is usually used for monitoring your brain cancer. In this research study you are being asked to have two MRI scans, one right before starting Bevacizumab (first dose) and another right before your 2-week (second) dose of Bevacizumab. The dynamic susceptibility contrast (DSC) MRI is also sometimes referred to as an advanced perfusion MRI. This is an existing standard of clinical practice at some centers, and optional at others. Some centers do not perform this. It will be performed with a contrast agent called gadolinium-based contrast agent (Gadavist) to help evaluate changes in the blood vessels within the cancer. There will be about 165 people taking part in this research study.
Description
DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Participating Institutions
Froedtert Hospital
Community Memorial Hospital
Status
OPEN TO ACCRUAL
Share This: